{"id":617568,"date":"2022-09-20T20:22:01","date_gmt":"2022-09-20T20:22:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=617568"},"modified":"2022-09-20T20:22:01","modified_gmt":"2022-09-20T20:22:01","slug":"sarcopenia-market-to-witness-upsurge-in-growth-during-the-forecast-period-20222032-examines-delveinsight-key-companies-biophytis-regeneron-pharmaceuticals-novartis-pharmaceuticals","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/sarcopenia-market-to-witness-upsurge-in-growth-during-the-forecast-period-20222032-examines-delveinsight-key-companies-biophytis-regeneron-pharmaceuticals-novartis-pharmaceuticals_617568.html","title":{"rendered":"Sarcopenia Market to Witness Upsurge in Growth During the Forecast Period (2022-2032), Examines DelveInsight | Key Companies &#8211; Biophytis, Regeneron Pharmaceuticals, Novartis Pharmaceuticals"},"content":{"rendered":"<div style=\"float:right;  width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1663676850.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Sarcopenia Market to Witness Upsurge in Growth During the Forecast Period (2022-2032), Examines DelveInsight | Key Companies - Biophytis, Regeneron Pharmaceuticals, Novartis Pharmaceuticals\" src=\"https:\/\/www.abnewswire.com\/uploads\/1663676850.jpeg\" alt=\"Sarcopenia Market to Witness Upsurge in Growth During the Forecast Period (2022-2032), Examines DelveInsight | Key Companies - Biophytis, Regeneron Pharmaceuticals, Novartis Pharmaceuticals\" width=\"225\" height=\"225\" \/><\/a><\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight\u2019s \u201cSarcopenia Market Insights, Epidemiology, and Market Forecast-2032\u2033 report offers an in-depth understanding of Sarcopenia, historical and forecasted epidemiology as well as the Sarcopenia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/div>\n<p style=\"text-align: justify;\">The <strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/sarcopenia-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Sarcopenia market<\/a> <\/strong>is expected to surge due to the disease&#8217;s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Sarcopenia pipeline products will significantly revolutionize the Sarcopenia market dynamics.&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Sarcopenia Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">Sarcopenia is a condition that is characterized by loss of muscle mass, muscle strength, and functional muscle impairment with aging. The definition has been through various alterations. However, an enormous recent breakthrough is the inclusion of the condition in the ICD-10 classification of diseases. The physical consequences of this disease put a person at risk for falls, fractures, and hospitalization, thereby affecting the quality of life and death in extreme cases.&nbsp;<\/p>\n<p style=\"text-align: justify;\">The etiology of sarcopenia is a constellation of factors involving the aging neuromuscular machinery (motor unit number and efficiency, muscle architecture and orientation, fiber type distribution), reduced anabolic hormone levels, muscle disuse, and inflammation, driven by environmental, genetic, and behavioral factors.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of the key facts of the Sarcopenia Market Report:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The Sarcopenia market size was estimated for <strong>USD 1,252 Million<\/strong> in the year 2021 and&nbsp; is anticipated to grow with a significant CAGR during the study period (2019-2032)<\/li>\n<li>The prevalence of sarcopenia depends on the definition applied and the attributes of the target population. Current definitions of sarcopenia are only newly developed and still not entirely accepted<\/li>\n<li>The total prevalent population of sarcopenia in the 7MM was found to be <strong>35,794,548 cases<\/strong> in 2021<\/li>\n<li>The total prevalent cases for sarcopenia were highest in the United States which accounted for approximately 53% of the total prevalent cases.<\/li>\n<li>Amongst the EU-5 countries, Italy had the highest number of cases followed by Germany with <strong>3,556,282<\/strong> and <strong>3,194,532<\/strong> cases respectively. Spain accounted for the least number of sarcopenia cases in 2021.<\/li>\n<li><strong>Key Sarcopenia Companies:<\/strong>&nbsp; Biophytis, Regeneron Pharmaceuticals, Novartis Pharmaceuticals, Merck Sharp &amp; Dohme LLC, Lipocine Inc., and others<\/li>\n<li><strong>Key Sarcopenia Therapies:<\/strong>&nbsp; Sarconeos, REGN1033, Bimagrumab, MK-0773, LPCN 1148, and others<\/li>\n<li>The Sarcopenia epidemiology based on gender analyzed that&nbsp; males are affected more as compared to females in case of sarcopenia<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Get a Free sample for the <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/sarcopenia-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Sarcopenia Market Report<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Key benefits of the Sarcopenia Market report:<\/strong><\/p>\n<ol style=\"text-align: justify;\" start=\"1\">\n<li>Sarcopenia market report covers a descriptive overview and comprehensive insight of the Sarcopenia Epidemiology and Sarcopenia market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) &amp; Japan.)<\/li>\n<li>The Sarcopenia market report provides insights on the current and emerging therapies.<\/li>\n<li>Sarcopenia market report provides a global historical and forecasted market covering drug outreach in 7MM.<\/li>\n<li>The Sarcopenia market report offers an edge that will help develop business strategies by understanding trends shaping and driving the Sarcopenia market.<\/li>\n<\/ol>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Discover more about therapies set to grab major Sarcopenia market share @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/sarcopenia-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Sarcopenia market forecast<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Sarcopenia Epidemiology Segmentation:<\/strong><\/p>\n<p style=\"text-align: justify;\">The Sarcopenia market report proffers epidemiological analysis for the study period 2019&ndash;2032 in the 7MM segmented into:<\/p>\n<ul style=\"text-align: justify;\">\n<li>Total Prevalence of Sarcopenia<\/li>\n<li>Prevalent Cases of Sarcopenia by severity<\/li>\n<li>Gender-specific Prevalence of Sarcopenia<\/li>\n<li>Diagnosed Cases of Episodic and Chronic Sarcopenia<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Sarcopenia Market&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">The dynamics of the Sarcopenia market are anticipated to change in the coming years owing to the expected launch of emerging therapies such as Sarconeos, and others during the forecasted period 2019-2032.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Download the report to understand which factors are driving Sarcopenia epidemiology trends @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/sarcopenia-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Sarcopenia Epidemiological Insights<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Sarcopenia Market Drivers<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Better insights into disease intervention<\/li>\n<li>Increase in research initiatives<\/li>\n<li>Need for a cost effective Sarcopenia therapy<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Sarcopenia Therapies and Key Companies<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Sarconeos:<\/strong> Biophytis<\/li>\n<li><strong>REGN1033:<\/strong> Regeneron Pharmaceuticals<\/li>\n<li><strong>Bimagrumab:<\/strong> Novartis Pharmaceuticals<\/li>\n<li><strong>MK-0773:<\/strong> Merck Sharp &amp; Dohme LLC<\/li>\n<li><strong>LPCN 1148:<\/strong> Lipocine Inc.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the Sarcopenia Market Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Study Period: 2019&ndash;2032<\/strong><\/li>\n<li><strong>Coverage:<\/strong> 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]<\/li>\n<li><strong>Key Sarcopenia Companies:<\/strong>&nbsp; Biophytis, Regeneron Pharmaceuticals, Novartis Pharmaceuticals, Merck Sharp &amp; Dohme LLC, Lipocine Inc., and others<\/li>\n<li><strong>Key Sarcopenia Therapies:<\/strong>&nbsp; Sarconeos, REGN1033, Bimagrumab, MK-0773, LPCN 1148, and others<\/li>\n<li><strong>Sarcopenia Therapeutic Assessment:<\/strong>&nbsp; Sarcopenia current marketed and Sarcopenia emerging therapies<\/li>\n<li><strong>Sarcopenia Market Dynamics:<\/strong>&nbsp; Sarcopenia market drivers and barriers&nbsp;<\/li>\n<li><strong>Competitive Intelligence Analysis:<\/strong>&nbsp; SWOT analysis, PESTLE analysis, Porter&rsquo;s five forces, BCG Matrix, Market entry strategies<\/li>\n<li><strong>Unmet Needs, KOL&rsquo;s views, Analyst&rsquo;s views, Sarcopenia&nbsp; Market Access and Reimbursement<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Sarcopenia Market Barriers<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Need for screening tools<\/li>\n<li>Implementation of interventions&nbsp;<\/li>\n<li>Diagnosis associated shortcomings<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents<\/strong><\/p>\n<p style=\"text-align: justify;\">1. Sarcopenia Market Report Introduction<\/p>\n<p style=\"text-align: justify;\">2. Executive Summary for Sarcopenia<\/p>\n<p style=\"text-align: justify;\">3. SWOT analysis of Sarcopenia<\/p>\n<p style=\"text-align: justify;\">4. Sarcopenia Patient Share (%) Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">5. Sarcopenia Market Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">6. Sarcopenia Disease Background and Overview<\/p>\n<p style=\"text-align: justify;\">7. Sarcopenia Epidemiology and Patient Population<\/p>\n<p style=\"text-align: justify;\">8. Country-Specific Patient Population of Sarcopenia&nbsp;<\/p>\n<p style=\"text-align: justify;\">9. Sarcopenia Current Treatment and Medical Practices<\/p>\n<p style=\"text-align: justify;\">10. Sarcopenia Unmet Needs<\/p>\n<p style=\"text-align: justify;\">11. Sarcopenia Emerging Therapies<\/p>\n<p style=\"text-align: justify;\">12. Sarcopenia Market Outlook<\/p>\n<p style=\"text-align: justify;\">13. Country-Wise Sarcopenia Market Analysis (2019&ndash;2032)<\/p>\n<p style=\"text-align: justify;\">14. Sarcopenia Market Access and Reimbursement of Therapies<\/p>\n<p style=\"text-align: justify;\">15. Sarcopenia Market drivers<\/p>\n<p style=\"text-align: justify;\">16. Sarcopenia Market barriers<\/p>\n<p style=\"text-align: justify;\">17.&nbsp; Sarcopenia Appendix<\/p>\n<p style=\"text-align: justify;\">18. Sarcopenia Report Methodology<\/p>\n<p style=\"text-align: justify;\">19. DelveInsight Capabilities<\/p>\n<p style=\"text-align: justify;\">20. Disclaimer<\/p>\n<p style=\"text-align: justify;\">21. About DelveInsight<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>To know more about Sarcopenia treatment, visit @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/sarcopenia-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Sarcopenia Medications<\/a><\/strong><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_75707.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Gaurav Bora<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=sarcopenia-market-to-witness-upsurge-in-growth-during-the-forecast-period-20222032-examines-delveinsight-key-companies-biophytis-regeneron-pharmaceuticals-novartis-pharmaceuticals\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=sarcopenia-market-to-witness-upsurge-in-growth-during-the-forecast-period-20222032-examines-delveinsight-key-companies-biophytis-regeneron-pharmaceuticals-novartis-pharmaceuticals\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight\u2019s \u201cSarcopenia Market Insights, Epidemiology, and Market Forecast-2032\u2033 report offers an in-depth understanding of Sarcopenia, historical and forecasted epidemiology as well as the Sarcopenia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/sarcopenia-market-to-witness-upsurge-in-growth-during-the-forecast-period-20222032-examines-delveinsight-key-companies-biophytis-regeneron-pharmaceuticals-novartis-pharmaceuticals_617568.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,423],"tags":[],"class_list":["post-617568","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Professional-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/617568","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=617568"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/617568\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=617568"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=617568"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=617568"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}